Results 171 to 180 of about 19,474 (223)

Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma. [PDF]

Nat Commun
Pedard M, Castillo Cantero L, Ghasemi A, Marinari E, Mollica C, Davanture S, Pernot J, Widmer V, Merkler D, Egervari K, Schaller K, Bijlenga P, Bartoli A, Momjian S, Pittet MJ, Dutoit V, Migliorini D.   +16 more
europepmc   +1 more source

Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell strategies. [PDF]

Neurosurg Rev
Carrion YL, Bhasin J, Anne S, Sawhney A, Ha CJ, Sharaf I, Santana J, Titkov K, Jean M, Thibault D, Pando A, Novakovic N, Parikh NS, Vojnic M, Sherman JH.   +14 more
europepmc   +1 more source

Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report. [PDF]

Front Pharmacol
Zhang T, Liao X, Li Y, Yang J, Shao J, Zhang H, Jiang S.   +6 more
europepmc   +1 more source

<i>In vitro</i> characterization of a novel anti-GD2/ROR1 bispecific antibody exhibiting tumor cell killing efficacy in neuroblastoma cross-cancer activity in ROR1-positive triple-negative breast cancer. [PDF]

Transl Cancer Res
Lin T, Chen X, Huang H, Zhang J, Xu Y, Lin J.   +5 more
europepmc   +1 more source

Next-generation CAR-T therapy for malignant brain tumors: latest updates from the 2026 AACR Annual Meeting. [PDF]

Exp Hematol Oncol
Costa Filho VO, Rabenhorst SHB, Mesquita FP.   +2 more
europepmc   +1 more source

CAR-T cell therapy: potential for paediatric brain tumours-an update. [PDF]

J Neurooncol
Zehner A, Draper B, Hargrave D, Donovan LK, Anderson J.   +4 more
europepmc   +1 more source

<i>FBN1</i> TB5 domain variants in acromelic dysplasia: multisystem manifestations, genotype-phenotype correlations, and partial responses to growth hormone therapy. [PDF]

Front Endocrinol (Lausanne)
Zhang J, Huang MT, Wang B, Lin YY, Zheng RJ, Xiao HM, Ma HM, Guo S, Chen QL, Li YH.   +9 more
europepmc   +1 more source

FECH, a novel metabolic target influencing CAR T-cell phenotype and function. [PDF]

Biomark Res
Pellegrino M, Vespa S, Salvatori I, Mac GD, Valle C, Secli V, Cairoli S, Goffredo BM, Caforio M, Folgiero V, Sanvi LW, Vulpis E, Ciampini E, Scarsella M, Giorda E, Chiaradonna F, Giansanti M, Nazio F, Ferri A, Cecconi F, Campello S, Velardi E, Caruana I, de Billy E.   +23 more
europepmc   +1 more source

CAR T-cell therapy in pediatric brain tumors: a narrative review with comparative analysis of clinical trial eligibility criteria. [PDF]

Front Oncol
Srinivasan A, Abraham A, Modak AI, Pradeep A, Nimachwala NL, Chemmancheri AV, Banu A, Azad AA, Abraham A, Khorbaladze L.   +9 more
europepmc   +1 more source